Literature DB >> 26209488

Increasing Frequency of Left Ventricular Assist Device Exchanges in the United States.

Fenton H McCarthy1, Dale Kobrin1, J Eduardo Rame2, Peter W Groeneveld3, Katherine M McDermott1, Pavan Atluri1, Michael A Acker1, Nimesh D Desai4.   

Abstract

BACKGROUND: Recent reports indicate an increased prevalence and earlier onset of pump thrombosis and associated pump exchanges after left ventricular assist device (LVAD) implantation. Questions remain regarding the current rate and clinical effect of pump exchanges.
METHODS: All United States Medicare fee-for-service patients undergoing LVAD implantations (n = 3,166) between January 2009 and December 2012 were identified by procedural codes present on carrier claims collected by the Centers for Medicare & Medicaid Services. Pump exchange, pump removal, heart transplantation, and death were collected from subsequent carrier claim and denominator files. Comorbidities present before implantation were generated using the Elixhauser comorbidity index.
RESULTS: Compared with patients who received LVADs before March 1, 2011, LVAD recipients after March 1, 2011, were older on average (63.9 vs 62.2 years, p < 0.01), more likely to be male (82.3% vs. 79.4%, p = 0.04), and had a higher incidence of common comorbidities. The later cohort had higher occurrence of pump exchange by Kaplan-Meier time-to-event estimates and Fisher exact tests at 3 months (1.8 vs 0.8, p = 0.02), 6 months (3.3 vs 1.0, p < 0.01), and 12 months (4.9 vs 2.2, p < 0.01). Cox regression analysis found time-dependent pump exchange was associated with worse survival (hazard ratio, 2.5; 95% confidence interval, 1.8 to 3.62; p < 0.01) after adjusting for age, gender, and comorbidities.
CONCLUSIONS: Although LVAD exchanges remain relatively uncommon, a significant increase in the incidence of the procedure has occurred since March 1, 2011. Pump exchanges are highly associated with death, and further research is required to understand the cause of this disturbing trend and surveillance to determine its trajectory.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26209488     DOI: 10.1016/j.athoracsur.2015.04.072

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

Review 1.  The future of left ventricular assist devices.

Authors:  Ahmet Kilic
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  Single lung retrieval from a donor supported by a left ventricular assist device.

Authors:  Keitaro Matsumoto; Naoya Yamasaki; Tomoshi Tsuchiya; Takuro Miyazaki; Ryotaro Kamohara; Go Hatachi; Kazuyoshi Tanigawa; Kiyoyuki Eishi; Takeshi Nagayasu
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

3.  Conservative approaches for HeartWare ventricular assist device pump thrombosis may improve the outcome compared with immediate surgical approaches.

Authors:  Diyar Saeed; Bujar Maxhera; Alexander Albert; Ralf Westenfeld; Till Hoffmann; Artur Lichtenberg
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-03-18

4.  Duration of Postoperative Atrial Fibrillation After Cardiac Surgery Is Associated With Worsened Long-Term Survival.

Authors:  Martin I Sigurdsson; Nicholas T Longford; Mahyar Heydarpour; Louis Saddic; Tzuu-Wang Chang; Amanda A Fox; Charles D Collard; Sary Aranki; Prem Shekar; Stanton K Shernan; Jochen D Muehlschlegel; Simon C Body
Journal:  Ann Thorac Surg       Date:  2016-07-15       Impact factor: 4.330

5.  Association of Cardiac Rehabilitation With Decreased Hospitalizations and Mortality After Ventricular Assist Device Implantation.

Authors:  Justin M Bachmann; Meredith S Duncan; Ashish S Shah; Robert A Greevy; JoAnn Lindenfeld; Steven J Keteyian; Randal J Thomas; Mary A Whooley; Thomas J Wang; Matthew S Freiberg
Journal:  JACC Heart Fail       Date:  2018-02       Impact factor: 12.035

6.  Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure -1 year results from the Ce mark trial.

Authors:  Thomas Krabatsch; Ivan Netuka; Jan D Schmitto; Daniel Zimpfer; Jens Garbade; Vivek Rao; Michiel Morshuis; Friedhelm Beyersdorf; Silvana Marasco; Laura Damme; Yuriy Pya
Journal:  J Cardiothorac Surg       Date:  2017-04-04       Impact factor: 1.637

7.  Left ventricular assist device exchange: the Toronto General Hospital experience.

Authors:  Hideki Tsubota; Roberto V P Ribeiro; Filio Billia; Robert J Cusimano; Terrence M Yau; Mitesh V Badiwala; William E Stansfield; Vivek Rao
Journal:  Can J Surg       Date:  2017-08       Impact factor: 2.089

8.  Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report.

Authors:  Jessica Howard-Anderson; Stephanie M Pouch; Mary Elizabeth Sexton; Aneesh K Mehta; Andrew L Smith; George M Lyon; Rachel Friedman-Moraco
Journal:  Open Forum Infect Dis       Date:  2019-09-04       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.